长春瑞滨持续静脉输注联合顺铂、大剂量三苯氧胺治疗晚期非小细胞肺癌  

Continuous intravenous drip vinorelbine plus cisplatin and large dose tamoxifen treatment for advanced non-small cell cancer

作　　者：陈日新[1] 逯华[1] 倪秉强[1] 伍美娟[1] 罗展雄[1] 徐艺安[1] 李旌[1] 朱州[1] 

机构地区：[1]广西柳州市人民医院肿瘤科,柳州545001

出　　处：《癌症进展》2006年第5期467-470,共4页Oncology Progress

摘　　要：目的观察长春瑞滨(NVB)持续静脉输注联合顺铂(DDP)、大剂量三苯氧胺(TAM)治疗晚期非小细胞肺癌(NSCLC)的疗效和毒性。方法经病理学或细胞学检查证实的45例晚期NSCLC随机分为两组,观察组25例采用持续静脉输注NVB+DDP+大剂量TAM,对照组20例采用持续静脉输注NVB+DDP。采用NP方案(NVB+DDP)。结果观察组CR5例,PR15例,总有效率80%,中位生存期13·5个月,1年、2年生存率分别为68%、36%;对照组CR1例,PR8例,总有效率为45%,中位生存期7·5个月,1年、2年生存率分别为36%、5%。两组毒性反应比较,差异均无显著性,主要为恶心、呕吐、骨髓抑制、感觉性神经病、脱发。结论NVB持续静脉输注联合DDP、大剂量TAM是治疗晚期NSCLC的较为有效而安全的新方法,值得进一步研究。To observe the effect and toxicity in advanced non - small cell lung cancer （NSCLC） after intravenous drip vinorelbine （NVB） plus cisplatin （DDP） and large dose tamoxifen （TAM）. Methods 45 NSCLC patients were testified by pathologic or cytologic diagnosis, were divided into two groups by random control test： Observe and control groups. 25 patients in the observe group were treated by continuous intravenous drip NVB plus DDP and large dose TAM. 20 patients in the control group were treated by continuous intraveno- us drip NVB plus DDP. Results In the observe group, 5 patients were completely remission （CR） and 15 patients,were partial remission （PR）, total effective rate （CR ＋ PR） was 80%, medium survival time was 13.5 months. In observe group, the 1 - , 2 - year survival rates were 68%, 36%. In the control group CR 1 case and PR 8 cases, total effective rate （CR＋ PR） was 45%, medium survival time was 7.5 months, 1 - , 2 - ysar survival rates were 36 %, 5 %. No statistical difference was noted in responses between these two groups toxic reaction, main toxic reaction were nausea, emesia, myelosuppression, esthesionosis, alopecie. Conclusion Continuous intravenous drip NVB plus DDP and large dose TAM is a new effective and safe method, in the treatment of advanced non - small cell lung cancer, we need to make a thorough study.

关 键 词：非小细胞肺癌 长春瑞滨 顺铂 三苯氧胺 化疗 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]